Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 [Yahoo! Finance]
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $10.00 price target on the stock.